Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.

ABSTRACT:

Objectives

Acute pain management in patients with opioid use disorder who are maintained on methadone presents unique challenges due to high levels of opioid tolerance in this population. This randomized controlled study assessed the analgesic and abuse liability effects of escalating doses of acute intravenous (IV) hydromorphone versus placebo utilizing a validated experimental pain paradigm, quantitative sensory testing (QST).

Methods

Individuals (N = 8) without chronic pain were maintained on 80-100 mg/day of oral methadone. Participants received four IV, escalating/incremental doses of hydromorphone over 270 min (32 mg total) or four placebo doses within a session test day. Test sessions were scheduled at least one week apart. QST and abuse liability measures were admini

SUBMITTER: Agin-Liebes G 

PROVIDER: S-EPMC9559787 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature